{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:26:08Z","timestamp":1758273968666,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08CA237872"],"award-info":[{"award-number":["K08CA237872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00345-020-03298-6","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T13:03:30Z","timestamp":1592571810000},"page":"1141-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["National trends in the management of patients with positive surgical margins at radical prostatectomy"],"prefix":"10.1007","volume":"39","author":[{"given":"Kamyar","family":"Ghabili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preston C.","family":"Sprenkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon P.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cary P.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"3298_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19941","author":"BA Mahal","year":"2019","unstructured":"Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D'Amico AV, Nguyen PL (2019) Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010\u20132015. JAMA. https:\/\/doi.org\/10.1001\/jama.2018.19941","journal-title":"JAMA"},{"issue":"4","key":"3298_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bju.14178","volume":"122","author":"C Herforth","year":"2018","unstructured":"Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ (2018) Radical prostatectomy and the effect of close surgical margins: results from the shared equal access regional cancer hospital (SEARCH) database. BJU Int 122(4):592\u2013598. https:\/\/doi.org\/10.1111\/bju.14178","journal-title":"BJU Int"},{"issue":"2","key":"3298_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2013.07.039","volume":"65","author":"O Yossepowitch","year":"2014","unstructured":"Yossepowitch O, Briganti A, Eastham JA, Epstein J, Graefen M, Montironi R, Touijer K (2014) Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol 65(2):303\u2013313. https:\/\/doi.org\/10.1016\/j.eururo.2013.07.039","journal-title":"Eur Urol"},{"issue":"1","key":"3298_CR4","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/j.clgc.2018.09.024","volume":"17","author":"F Preisser","year":"2019","unstructured":"Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF, Tian Z, Saad F, Montorsi F, Zorn KC, Graefen M, Tilki D, Karakiewicz PI (2019) Rates of positive surgical margins and their effect on cancer-specific mortality at radical prostatectomy for patients with clinically localized prostate cancer. Clin Genitourin Cancer 17(1):e130\u2013e139. https:\/\/doi.org\/10.1016\/j.clgc.2018.09.024","journal-title":"Clin Genitourin Cancer"},{"issue":"9485","key":"3298_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(05)67101-2","volume":"366","author":"M Bolla","year":"2005","unstructured":"Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Marechal JM, Scalliet P, Haustermans K, Pierart M, European Organization for R, Treatment of C (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572\u2013578. https:\/\/doi.org\/10.1016\/S0140-6736(05)67101-2","journal-title":"Lancet"},{"issue":"19","key":"3298_CR6","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","volume":"296","author":"IM Thompson Jr","year":"2006","unstructured":"Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296(19):2329\u20132335. https:\/\/doi.org\/10.1001\/jama.296.19.2329","journal-title":"JAMA"},{"issue":"18","key":"3298_CR7","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.2008.18.9563","volume":"27","author":"T Wiegel","year":"2009","unstructured":"Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M, Rube C, Weissbach L, Althaus P, Rebmann U, Kalble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96\u201302\/AUO AP 09\/95. J Clin Oncol 27(18):2924\u20132930. https:\/\/doi.org\/10.1200\/JCO.2008.18.9563","journal-title":"J Clin Oncol"},{"issue":"2","key":"3298_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.juro.2013.05.032","volume":"190","author":"IM Thompson","year":"2013","unstructured":"Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr, Faraday MM (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA\/ASTRO Guideline. J Urol 190(2):441\u2013449. https:\/\/doi.org\/10.1016\/j.juro.2013.05.032","journal-title":"J Urol"},{"issue":"4","key":"3298_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618\u2013629. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003","journal-title":"Eur Urol"},{"issue":"3","key":"3298_CR10","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1016\/j.clgc.2014.12.005","volume":"13","author":"BA Mahal","year":"2015","unstructured":"Mahal BA, Hoffman KE, Efstathiou JA, Nguyen PL (2015) National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. Clin Genitourin Cancer 13(3):e167\u2013172. https:\/\/doi.org\/10.1016\/j.clgc.2014.12.005","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"3298_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.eururo.2015.04.003","volume":"68","author":"HM Sineshaw","year":"2015","unstructured":"Sineshaw HM, Gray PJ, Efstathiou JA, Jemal A (2015) Declining use of radiotherapy for adverse features after radical prostatectomy: results from the national cancer data base. Eur Urol 68(5):768\u2013774. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.003","journal-title":"Eur Urol"},{"key":"3298_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.urology.2017.06.054","volume":"109","author":"B Bhindi","year":"2017","unstructured":"Bhindi B, Carlson RE, Mason RJ, Schulte PJ, Gettman MT, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Leibovich BC, Karnes RJ (2017) Long-term follow-up of a matched cohort study evaluating the role of adjuvant radiotherapy for organ-confined prostate cancer with a positive surgical margin. Urology 109:145\u2013152. https:\/\/doi.org\/10.1016\/j.urology.2017.06.054","journal-title":"Urology"},{"issue":"4","key":"3298_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.eururo.2015.10.009","volume":"69","author":"N Fossati","year":"2016","unstructured":"Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A (2016) Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 69(4):728\u2013733. https:\/\/doi.org\/10.1016\/j.eururo.2015.10.009","journal-title":"Eur Urol"},{"issue":"6","key":"3298_CR14","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.eururo.2013.03.058","volume":"65","author":"S Punnen","year":"2014","unstructured":"Punnen S, Freedland SJ, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR (2014) Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol 65(6):1171\u20131177. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.058","journal-title":"Eur Urol"},{"issue":"1","key":"3298_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ucl.2015.08.002","volume":"43","author":"MS Leapman","year":"2016","unstructured":"Leapman MS, Carroll PR (2016) New genetic markers for prostate cancer. Urol Clin North Am 43(1):7\u201315. https:\/\/doi.org\/10.1016\/j.ucl.2015.08.002","journal-title":"Urol Clin North Am"},{"issue":"3","key":"3298_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15(3):683\u2013690. https:\/\/doi.org\/10.1245\/s10434-007-9747-3","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"3298_CR17","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1002\/cncr.26169","volume":"117","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg MR, Hilton JF, Carroll PR (2011) The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117(22):5039\u20135046. https:\/\/doi.org\/10.1002\/cncr.26169","journal-title":"Cancer"},{"issue":"19","key":"3298_CR18","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/cncr.28856","volume":"120","author":"A Kalbasi","year":"2014","unstructured":"Kalbasi A, Swisher-McClure S, Mitra N, Sunderland R, Smaldone MC, Uzzo RG, Bekelman JE (2014) Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features. Cancer 120(19):3089\u20133096. https:\/\/doi.org\/10.1002\/cncr.28856","journal-title":"Cancer"},{"issue":"6","key":"3298_CR19","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1016\/j.juro.2007.08.008","volume":"178","author":"JA Smith Jr","year":"2007","unstructured":"Smith JA Jr, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS (2007) A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol 178(6):2385\u20132389. https:\/\/doi.org\/10.1016\/j.juro.2007.08.008 (Discussion 2389-2390)","journal-title":"J Urol"},{"issue":"1","key":"3298_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0022-5347(01)64044-8","volume":"159","author":"PJ Van Cangh","year":"1998","unstructured":"Van Cangh PJ, Richard F, Lorge F, Castille Y, Moxhon A, Opsomer R, De Visscher L, Wese FX, Scaillet P (1998) Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol 159(1):164\u2013166","journal-title":"J Urol"},{"issue":"8","key":"3298_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/COC.0000000000000358","volume":"41","author":"MP Shaikh","year":"2018","unstructured":"Shaikh MP, Alite F, Wu MJ, Solanki AA, Harkenrider MM (2018) Adjuvant radiotherapy versus wait-and-see strategy for pathologic T3 or margin-positive prostate cancer: a meta-analysis. Am J Clin Oncol 41(8):730\u2013738. https:\/\/doi.org\/10.1097\/COC.0000000000000358","journal-title":"Am J Clin Oncol"},{"issue":"3 Pt 1","key":"3298_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.juro.2016.09.079","volume":"197","author":"E Zaffuto","year":"2017","unstructured":"Zaffuto E, Gandaglia G, Fossati N, Dell'Oglio P, Moschini M, Cucchiara V, Suardi N, Mirone V, Bandini M, Shariat SF, Karakiewicz PI, Montorsi F, Briganti A (2017) Early postoperative radiotherapy is associated with worse functional outcomes in patients with prostate cancer. J Urol 197(3 Pt 1):669\u2013675. https:\/\/doi.org\/10.1016\/j.juro.2016.09.079","journal-title":"J Urol"},{"issue":"1","key":"3298_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.clgc.2016.07.009","volume":"15","author":"AT Wong","year":"2017","unstructured":"Wong AT, Schwartz D, Lee A, Safdieh J, Osborn V, Schreiber D (2017) Patterns of postprostatectomy adjuvant radiotherapy techniques for nonmetastatic prostate cancer in a large national cohort. Clin Genitourin Cancer 15(1):168\u2013175. https:\/\/doi.org\/10.1016\/j.clgc.2016.07.009","journal-title":"Clin Genitourin Cancer"},{"key":"3298_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000410","author":"DD Yang","year":"2017","unstructured":"Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF 3rd, King MT, Nguyen PL (2017) Travel distance as a barrier to receipt of adjuvant radiation therapy after radical prostatectomy. Am J Clin Oncol. https:\/\/doi.org\/10.1097\/COC.0000000000000410","journal-title":"Am J Clin Oncol"},{"key":"3298_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.01.006","author":"SR Hawken","year":"2019","unstructured":"Hawken SR, Spratt DE, Qi J, Linsell SM, Cher ML, Ghani KR, Miller DC, Montie JE, Morgan TM, Michigan Urological Surgery Improvement C (2019) Utilization of salvage radiation therapy for biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.01.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"3298_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, RTOG NRGO (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376(5):417\u2013428. https:\/\/doi.org\/10.1056\/NEJMoa1607529","journal-title":"N Engl J Med"},{"issue":"5","key":"3298_CR27","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.ijrobp.2018.08.052","volume":"102","author":"A Pollack","year":"2018","unstructured":"Pollack A, Karrison TG, Balogh AG Jr, Low D, Bruner DW, Wefel JS, Gomella LG, Vigneault E, Michalski JM, Angyalfi S, Lukka H, Faria SL, Rodrigues G, Beauchemin MC, Seaward SA, Allen AM, Monitto DC, Seiferheld W, Sandler HM (2018) Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology\/RTOG 0534 SPPORT Trial. Int J Radiat Oncol Biol Phys 102(5):1605. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.08.052","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3298_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.eururo.2015.05.036","volume":"69","author":"RC Chen","year":"2016","unstructured":"Chen RC (2016) Postprostatectomy radiotherapy: whether and how long to give concurrent androgen deprivation therapy. Eur Urol 69(1):58\u201359. https:\/\/doi.org\/10.1016\/j.eururo.2015.05.036","journal-title":"Eur Urol"},{"issue":"18","key":"3298_CR29","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1002\/cncr.28222","volume":"119","author":"NC Sheets","year":"2013","unstructured":"Sheets NC, Hendrix LH, Allen IM, Chen RC (2013) Trends in the use of postprostatectomy therapies for patients with prostate cancer: a surveillance, epidemiology, and end results medicare analysis. Cancer 119(18):3295\u20133301. https:\/\/doi.org\/10.1002\/cncr.28222","journal-title":"Cancer"},{"issue":"3","key":"3298_CR30","doi-asserted-by":"publisher","first-page":"109.e107","DOI":"10.1016\/j.urolonc.2014.11.005","volume":"33","author":"HS Dev","year":"2015","unstructured":"Dev HS, Wiklund P, Patel V, Parashar D, Palmer K, Nyberg T, Skarecky D, Neal DE, Ahlering T, Sooriakumaran P (2015) Surgical margin length and location affect recurrence rates after robotic prostatectomy. Urol Oncol 33(3):109.e107\u2013113. https:\/\/doi.org\/10.1016\/j.urolonc.2014.11.005","journal-title":"Urol Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03298-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T23:29:34Z","timestamp":1624058974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03298-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3298"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03298-6","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"type":"print","value":"0724-4983"},{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Park has received honoraria from Varian Medical Systems, Inc., and Rad Onc Queestions, LLC. Dr. Yu has received research funding from 21st Century Oncology, and consulting fees from Augmenix Inc. Dr. Sprenkle serves as a consultant for Boston Scientific and GenomeDx Biosciences. Dr. Ma has received research funding from Celgene Corp. Dr. Gross has received research funding from NCCN\/Pfizer, and travel funding from Flatiron, and funding from Johnson & Johnson to help design new approaches for sharing clinical trial data. Dr. Leaspman has received research funding from BESO Biologic. Dr. Ghabili, Mr. Nguyen, and Dr. Kim declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}